Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03000049

Acronym

BEMIDIA

Enrollment

500

Registered

2016-12-21

Start date

2016-11-30

Completion date

2017-09-30

Last updated

2016-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis Septic Shock

Keywords

sepsis, septic shock, blood cultures, anti-infective therapy

Brief summary

With a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System) it is possible to optimize the initial antimicrobial therapy in patients with sepsis and septic shock. Prospective observational, open-label mono-center study to compare a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System and Curetis Univero System) with standard blood culture diagnostics in patients with sepsis or septic shock.

Interventions

OTHERbedside blood culture

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with a new diagnosed sepsis or septic shock: emergency department, operating theatre, intensive care unit and planed blood culture diagnostics. * informed written consent

Exclusion criteria

* Pediatric patients (\< 18 Years) * DNR-order

Design outcomes

Primary

Measure	Time frame
Time to a significant change of antimicrobial therapy from the time of the diagnosis of sepsis or septic shock	Nov. 2016 - Nov. 2017

Countries

Germany

Contacts

Primary ContactMatthias Gründling, MD

gruendli@uni-greifswald.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026